EXEL vs GMAB
Exelixis, Inc. and Genmab A/S, both Healthcare
Genmab A/S is the larger company at $16B against $13B. Over the past year EXEL returned +49% against +31% for GMAB. The RyuScore puts GMAB ahead, 84 against 80 out of 100.
| Figure | EXEL | GMAB |
|---|---|---|
| Last close | $59.86 | $37.06 |
| Market cap | $13B | $16B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.8 | n/a |
| 1-year return | +49% | +31% |
| 5-year return | +197% | -15% |
| RyuScoresector-relative, 1–10 | 80/100 | 84/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Exelixis, Inc.
Revenue of $629M in Q2 2026, net income $212M. Its largest reported line is Product Gross, 87% of the disclosed total.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.